Kestra Medical Technologies, Ltd. Common Stock KMTS

Kestra Medical Technologies, Inc. es una empresa comercial de dispositivos médicos portátiles y salud digital en etapa de comercialización. La compañía se enfoca en transformar los resultados de los pacientes con enfermedades cardiovasculares utilizando tecnologías de monitoreo e intervención terapéutica. Ha desarrollado y comercializado su plataforma Cardiac Recovery System, un sistema integral y avanzado que integra monitoreo, tratamiento terapéutico, salud digital y servicios de apoyo al paciente en una solución unificada. Su plataforma Cardiac Recovery System incluye el ASSURE WCD, un desfibrilador cardioversor portátil de próxima generación (WCD) utilizado para proteger a pacientes con un riesgo elevado de paro cardíaco repentino (PCR). El ASSURE WCD monitorea automáticamente a los pacientes con riesgo elevado y, si es necesario, administra una descarga de desfibrilación para devolver el ritmo cardíaco del paciente a la normalidad. Además del ASSURE WCD, su plataforma Cardiac Recovery System incluye una amplia gama de soluciones digitales y servicios totalmente integrados.

• Zacks Investment Research 14 sept

  Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates

  Kestra Medical Technologies reported a Q1 loss of $0.75 per share, missing EPS expectations of $0.61 by 22.95%, though it exceeded revenue estimates with $30.97 million (6.66% above consensus). The company has underperformed the S&P 500 by 25.7% year-to-date and carries a Zacks Rank #3 (Hold) rating, with mixed estimate revisions ahead.

  

• GlobeNewswire Inc. 10 sept

  Kestra Names Daniel Finney Vice President of Research & Development

  Kestra Medical Technologies announced the appointment of Daniel Finney as Vice President of Research & Development and executive leadership team member. Finney, who has over 20 years of medical device development experience, succeeds Phillip D. Foshee, Jr. and will lead the company's innovation initiatives across the Cardiac Recovery System platform, including AI applications and strategic partnerships.

  

• Zacks Investment Research 2 sept

  Phreesia (PHR) Q2 Earnings and Revenues Lag Estimates

  Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.

  

• GlobeNewswire Inc. 26 ago

  Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience

  Kestra Medical Technologies announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience in a newly created role. Kopf, who previously led global customer experience at Insulet Corporation and served as Chief Experience Officer at REI, will oversee the patient experience for the ASSURE WCD device. The appointment aligns with Kestra's investments in commercial capabilities and artificial intelligence initiatives to drive growth and improve patient support throughout their cardiac recovery journey.